Performance and internal validation of the HIGH-2-LOW RAM
| . | Risk assessment category* . | Risk score . | OR for VTE (95% CI) . | VTE incidence 30 to 100 d,† % . | C-statistic‡ (95% CI) . |
|---|---|---|---|---|---|
| Primary analysis Overall VTE as outcome at day 100 | Low (n = 921) | 0 | 1 | 1.54 | 0.69 (0.62-0.76) |
| Intermediate (n = 507) | 1 | 2.71 (1.38-5.35) | 3.58 | ||
| High (n = 275) | 2+ | 5.87 (2.98-11.57) | 10.25 | ||
| Sensitivity analysis 1 PE or LE-DVT (not CR-DVT) as outcome at day 100 | Low (n = 921) | 0 | 1 | 0.66 | 0.71 (0.60-0.81) |
| Intermediate (n = 507) | 1 | 3.01 (1.06-8.50) | 1.51 | ||
| High (n = 275) | 2+ | 7.43 (2.72-20.31) | 5.56 | ||
| Sensitivity analysis 2 Overall VTE at day 100 in patients with platelet recovery >50 × 109/L at day 30 | Low (n = 754) | 0 | 1 | 1.21 | 0.73 (0.65-0.80) |
| Intermediate (n = 363) | 1 | 3.32 (1.42-7.75) | 3.94 | ||
| High (n = 197) | 2+ | 9.35 (4.19-20.89) | 11.05 |
| . | Risk assessment category* . | Risk score . | OR for VTE (95% CI) . | VTE incidence 30 to 100 d,† % . | C-statistic‡ (95% CI) . |
|---|---|---|---|---|---|
| Primary analysis Overall VTE as outcome at day 100 | Low (n = 921) | 0 | 1 | 1.54 | 0.69 (0.62-0.76) |
| Intermediate (n = 507) | 1 | 2.71 (1.38-5.35) | 3.58 | ||
| High (n = 275) | 2+ | 5.87 (2.98-11.57) | 10.25 | ||
| Sensitivity analysis 1 PE or LE-DVT (not CR-DVT) as outcome at day 100 | Low (n = 921) | 0 | 1 | 0.66 | 0.71 (0.60-0.81) |
| Intermediate (n = 507) | 1 | 3.01 (1.06-8.50) | 1.51 | ||
| High (n = 275) | 2+ | 7.43 (2.72-20.31) | 5.56 | ||
| Sensitivity analysis 2 Overall VTE at day 100 in patients with platelet recovery >50 × 109/L at day 30 | Low (n = 754) | 0 | 1 | 1.21 | 0.73 (0.65-0.80) |
| Intermediate (n = 363) | 1 | 3.32 (1.42-7.75) | 3.94 | ||
| High (n = 197) | 2+ | 9.35 (4.19-20.89) | 11.05 |
Score category determined by the sum of the weights of the proposed covariates of interest, with low risk = 0, intermediate risk = 1, and high risk ≥2.
The incidence reported here is an underestimate of the overall incidence of VTE posttransplant, as it represents incident VTE events that occur from day 30 to day 100 (70-d span).
The c-statistic is reported after optimism adjustment, and the bias-corrected CI was derived from bootstrapping the resample 1000 times. The final model calibration and goodness-of-fit are shown in the supplemental figures.